(S)-ketamine for Mild and Moderate AUD
(S)-ketamine in combination with psycho-social support to treat Mild and Moderate AUD
Re-purpose and develop (S)-ketamine, in a proprietary formulation, as a marketed combined therapeutic to treat Mild and Moderate AUD.
Awakn has signed 18-month exclusive agreement with a European pharmaceutical company to test the suitability of a proprietary formulation of (S)-ketamine with Phase I completed.
(S)-KETAMINE TO TREAT MILD and MODERATE AUD – Timeline
Sign Up for Newsletter